RO 106-9920 is a cell-permeable tetrazolopyridazine-phenylsulfoxide compound that displays anti-inflammatory properties. RO 106-9920 acts as a highly selective, irreversible inhibitor of IκBaee ubiquitination. RO 106-9920 blocks NF-κB-dependent cytokine expression in human PBMNs and rats. RO 106-9920 does not inhibit SCFbTRCP (IκBa ubiquitin ligase)-mediated b-catenin ubiquitination in Jurkat cells. At 10 μM concentrations, this compound also inhibits the activities of 5-LO (5-lipoxygenase), EGFR kinase and NOS2 (iNOS).
1. Swinney, D.C., et al. 2002. J. Biol. Chem. 277: 23573-23581. PMID: 11950839
See how others have used RO 106-9920. Click on the entry to view the PubMed entry .
PMID: # 26670488 2016. Am. J. Physiol. Endocrinol. Metab. 310: E289-300.
PMID: # 25965265 Rajalakshmy, AR. et al. 2015. PLoS ONE. 10: e0125419.
PMID: # 23359428 2013. J. Cell. Physiol. 228: 1745-53.
PMID: # 23028567 2012. PLoS ONE. 7: e44622.
PMID: # 22847000 Narayanan, A. et al. 2012. The Journal of biological chemistry. 287: 33198-214.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.